LÍNEA DIRECTA ASEGURADORA, S.A., COMPAÑÍA DE SEGUROS Y REASEGUROS

FULL TEXTS OF THE PROPOSED RESOLUTIONS

GENERAL SHAREHOLDERS' MEETING

One. - Examination and approval of the individual Financial Statements and the Individual Management Report of Línea Directa Aseguradora, S.A. Compañía de Seguros y Reaseguros, and of the consolidated Financial Statements and the consolidated Management Report of Línea Directa Aseguradora, S.A., Compañía de Seguros y Reaseguros and its subsidiaries, all corresponding to the financial year ended 31 December 2025

Approval of the individual Financial Statements and the individual Management Report of Línea Directa Aseguradora, S.A., Compañía de Seguros y Reaseguros as well as approval of the consolidated Financial Statements and the consolidated Management Report of Línea Directa Aseguradora, S.A., Compañía de Seguros y Reaseguros and its subsidiaries, all corresponding to the financial year ended 31 December 2025 as drawn up by the Company's Board of Directors at its meeting on 19 February 2026.

Two. - Examination and approval of the consolidated Non-Financial Information Statement and Sustainability Information corresponding to the financial year ended 31 December 2025, included in the consolidated Group Management Report.

To approve the Consolidated Non-Financial Information Statement and Sustainability Information for the financial year ended December 31, 2025, which forms part of the Group’s consolidated Management Report, as prepared by the Company’s Board of Directors at its meeting held on February 19, 2026.

Three. - Examination and approval of the proposed distribution of earnings and dividends for the financial year ended 31 December 2025.

Approval of the distribution of profits earnings by the Company in the financial year ended 31 December 2025 amounting to 78,208,532.05 euros by distributing it as follows:

linea directa

To interim dividends	30,017,118.16
To interim equalisation reserve	9,219,462.91
To the voluntary reserve	23,971,950.98
To the final dividend	15,000,000.00

At meetings held on 24 June 2025 and 20 November 2025, the Company's Board of Directors resolved to pay shareholders an interim dividend of 0.013800 and 0.013789 euros gross per share, respectively, at each of the sessions indicated, amounting to a total of EUR 30,000,000 in interim dividends.

Such dividends were paid, with Banco Santander, S.A. acting as the paying agent, on July 1, 2025, and December 5, 2025, respectively. In this regard, it is agreed to ratify, in all that is necessary, the resolutions of the Board of Directors dated June 24, 2025 and November 20, 2025.

Consequently, the final dividend payable to shareholders amounts to 0.01379 euros gross per share, representing an approximate gross amount of EUR 15 million. The amount corresponding to treasury shares has been distributed pro rata among the remaining shares.

The payment of the supplementary dividend will be made in accordance with IBERCLEAR's operating regulations, with Banco Santander, S.A. acting as the paying agent, and the relevant dates for this purpose will be as follows:

- Last trading date on which the Company's shares trade with entitlement to receive the dividend (Last Trading Date): 17 April 2026
- Date from which the Company's shares trade without entitlement to receive the dividend (Ex-date): 20 April 2026
- Date on which the eligible registered holders entitled to claim payment from the Company are determined (Record date): 21 April 2026
- Payment date: 22 April 2026

Accordingly, the total dividend for financial year 2025 amounts to 45,000,000 EUR , that is, 0.041380 euros gross per share.

Four. - Examination and approval of the management of the Board of Directors during the financial year ended 31 December 2025.

Approval of the corporate management and the actions carried out by the Company's Board of Directors during the financial year ended 31 December 2025.

Five. - Appointment of the Company's and the Consolidated Group's Auditors for the 2026, 2027 and 2028 Financial Years.

In accordance with the proposal made by the Company's Audit and Compliance Committee, and following the convening and completion of a tender process, to appoint

PricewaterhouseCoopers Auditores, S.L., with registered office in Madrid, Paseo de la Castellana No. 259 B, and Tax Identification Number (N.I.F.) B-79031290, registered in the Official Register of Auditors of Accounts of Spain under number S-0242, and in the Commercial Registry of Madrid, Volume 9,267, Book 8,054, Page 75, Section 3, Sheet 87250-1, as the Auditors of the Financial Statements of Línea Directa Aseguradora, S.A., Compañía de Seguros y Reaseguros, and its Consolidated Group for the financial years 2026, 2027, and 2028. They are likewise entrusted with carrying out any other audit services required by law that the Company may need for those same financial years.

The Board of Directors of the Company is expressly authorized, with the power of delegation to the Chief Executive Officer, to enter, where appropriate, into the corresponding service agreement with PricewaterhouseCoopers Auditores, S.L. for the applicable term and under the conditions and clauses required in each case.

Six. - Re-election of Ms Patricia Ayuela de Rueda as Executive Director.

To re-elect, at the proposal of the Board of Directors, Ms Patricia Ayuela de Rueda a as a member of the Board of Directors of Línea Directa Aseguradora, S.A., Compañía de Seguros y Reaseguros, for the statutory term of four years, with the status of executive director, on the terms provided for in the Company's By-laws and in the applicable regulations.

In compliance with sections 4 and 5 of Article 529 decies of the Capital Companies Act, approved by Royal Legislative Decree 1/2010, of 2 July, it is hereby recorded that: (i) the Company's Board of Directors proposed the re-election of Ms Patricia Ayuela de Rueda at its meeting held on 19 February 2026; and (ii) said re-election proposal was supported by the required suitability assessment report regarding Ms. Patricia Ayuela de Rueda, issued by the Appointments, Remuneration and Corporate Governance Committee and by the Board of Directors on 17 and 19 February 2026, respectively.

Seven. - **Maintenance of the vacancy and the number of members of the Board of Directors.**

Maintain the number of members of the Company's Board of Directors at eight (8), leaving, for the time being, unfilled the vacancy caused by the death of Mr. John de Zulueta Greenebaum, and authorise the Board of Directors to defer the filling of such vacancy to a time after this General Meeting, so that the Board continues to operate with seven (7) directors until it validly completes the selection process in accordance with the Company's Directors' Selection and Succession Policy and fills the vacancy by co-option, pursuant to the provisions of the Capital Companies Act and the Company's Bylaws, and, where applicable, subsequently submits such appointment for ratification by the first General Shareholders' Meeting to be held.

Eight. - **Approval of a Long-Term Incentive Plan 2026-2028.**

To approve, in accordance with Article 219 of the Spanish Companies Act and Article 31 of the Corporate Bylaws, the 2026–2028 long-term variable remuneration plan (hereinafter, the "**Plan**") aimed at the members of the Management Team, including the Chief Executive Officer, and certain key or relevant individuals Línea Directa Aseguradora, S.A. ("**Línea Directa Aseguradora**" or the "**Company**").

linea directa

The characteristics of the Plan are aligned with the Directors' Remuneration Policy approved, in accordance with Article 529 novodecies of the Spanish Companies Act, by the General Shareholders' Meeting held on April 10, 2025 (the "**Remuneration Policy**"). The basic terms and conditions of the Plan are as follows:

<u>Description and purpose of the Plan:</u>

The purpose of the Plan is to motivate and retain certain individuals considered key or relevant to the achievement of the Company's medium- and long-term strategic objectives (the "**Beneficiaries**"), helping to retain and incentivise Línea Directa Aseguradora's key workforce, improve the Company's profit and loss account in the medium and long term, and support the Company's sustainability.

It will allow its beneficiaries to receive, after a specified period of time and provided that certain requirements and the Company's strategic objectives are met, remuneration to be settled, in equal parts, in a specified number of ordinary shares of Línea Directa Aseguradora and a specified cash amount.

For this purpose, the Plan is implemented through the granting to each beneficiary of a target incentive (the "**Target Incentive**"), which will serve to calculate, based on the degree of achievement of the objectives to which the Plan is linked (hereinafter, the "**Degree of Achievement of the Objectives**"), the number of shares to be delivered and the amount of the incentive to be settled in cash (jointly, the "**Incentive**").

<u>Beneficiaries of the Plan</u>: The Chief Executive Officer, the members of the Management Team, and certain key or relevant individuals of the Company who are expressly invited by the Company's Board of Directors, upon proposal by the Appointments, Remuneration and Corporate Governance Committee (the "CNRGC"), and who expressly accept to participate, shall be considered Beneficiaries of the Plan

The estimated number of Plan Beneficiaries is approximately 40 individuals, without prejudice to any additional Beneficiaries that the Board of Directors may approve for inclusion in the Plan during its term.

<u>Duration and settlement</u>**:** The Plan will formally commence on the date of its approval by the 2026 General Shareholders' Meeting (the **"Start Date"**).

The Plan's performance measurement period (**the "Measurement Period"**) will run from 1 January 2026 (the **"Measurement Period Start Date"**) to 31 December 2028 (the **"Measurement Period End Date"**).

After the end of the Measurement Period, the amount of the Incentive that each Beneficiary may be entitled to receive will be determined based on the Degree of Achievement of the Objectives, and it will be settled within sixty days following the approval of the 2028 annual accounts (the **"Settlement Date"**).

The delivery of the Company's shares, as well as the payment of any cash amount arising under the Plan, will be made in compliance with the deferral requirements and procedures set out in the Directors' Remuneration Policy, where applicable, in accordance with the following schedule:

- 60% of the Incentive amount will be settled, in equal halves, in cash and in shares, on the Settlement Date.
- The remaining 40% of the Incentive will be settled, in equal halves, in cash and in shares, on a deferred basis, in three equal instalments, over a three-year period.

Determination of the Incentive: The amount of the Incentive that each Beneficiary will receive under the Plan will be determined in accordance with the following formula:

$$I = \text{Target Incentive} \times GCI$$

Where:

• I = Incentive that will be settled, in equal parts, through the payment of a certain amount in cash and the delivery of a certain number of the Company's shares.

• Target Incentive ("TI") = Target incentive communicated to the Beneficiary in the Invitation Letter.

• GCI = Degree of Achievement of the Objectives, expressed as a percentage, based on the level of achievement, during the Measurement Period, of the objectives to which the Plan is linked.

Maximum number of shares: The maximum number of shares to be delivered under the Plan amounts to de 12,611,210 ordinary shares of the Company, representing 1.16% of the share capital, without prejudice to any adjustments, where applicable, resulting from variations in the value of the Línea Directa share at the time of settlement. A maximum of 741,726 shares are allocated to the Chief Executive Officer.

Among other means, the Company may use, to cover the Plan and subject to the fulfilment of the applicable legal requirements: (i) treasury shares of Línea Directa Aseguradora Línea Directa Aseguradora , S.A. that it has acquired or may acquire in the future; or (ii) newly issued shares of Línea Directa Aseguradora, S.A.

Reference value for determining the number of shares to be delivered: To determine the number of shares to be delivered under the Plan, the average share price of the Company from 1 to 31 January 2029 shall be taken as the reference value.

Objectives of the Plan: The Degree of Achievement of the Incentive, which will determine the Incentive to be settled in cash and the number of shares to be delivered under the Plan, shall depend on the level of fulfilment of the following strategic objectives of the Company (the "**Objectives**") during the Measurement Period, based on the weighting assigned to each of them:

- **Group combined ratio**, weighted at 40% in determining the Incentive.
- **Growth in Línea Directa's premiums** during the Plan's Measurement Period compared to the non-life sector, provided that Línea Directa Aseguradora's cumulative growth over that period is at least 15% during the Measurement Period. This objective will be weighted at 50% in determining the Incentive.

- **Evolution of the Service Quality indicator**, based on ICEA's ranking of insurance companies regarding the Net Promoter Score ("NPS"), weighted at 10% in determining the Incentive.

Requirements for receiving the Incentive: The requirements that must be cumulatively met for each of the Beneficiaries to vest the right to receive the Incentive under the Plan are as follows:

- achieving a minimum threshold of fulfilment of the Plan Objectives; and
- maintaining an active relationship, whether employment-based or commercial, with the Company until the End Date of the Measurement Period, without prejudice to any special cases of termination or suspension, among others, that may be established by the Board of Directors.

Malus and clawback clauses:

The Plan shall include the corresponding reduction ("malus") and recovery ("clawback") clauses set out in the Remuneration Policy

Share retention period: In accordance with the terms set out in the Remuneration Policy, the shares delivered under the Plan to the Chief Executive Officer may not be disposed of or transferred until a period of at least three years has elapsed.

An exception shall apply if, at the time of the transfer, the Chief Executive Officer maintains a net economic exposure to changes in the share price with a market value equivalent to at least twice her annual fixed remuneration, through the ownership of shares, options or other financial instruments.

The foregoing shall not apply to the shares that the Chief Executive Officer needs to dispose of in order to cover the costs related to their acquisition or, subject to a favourable assessment by the CNRGC Committee, to address extraordinary unforeseen circumstances that may so require.

Management and administration of the Plan:

The Board of Directors is authorised, to the fullest extent, and may delegate these powers to the CNRGC, the Chief Executive Officer, or any other person expressly empowered by the Board of Directors for this purpose, to implement this resolution and, among other matters, to interpret, implement, develop, formalise, execute and settle the Plan whenever and however it deems appropriate, adopting any resolutions and signing any public or private documents that may be necessary or advisable for the Plan to be fully effective, including the power to remedy, correct, amend or supplement this resolution. These powers include the authority to replace the ICEA ranking with another analogous index in the event that such ranking ceases to be published or is substantially modified.

In general, the Board is empowered to adopt any resolutions and carry out any actions that may be necessary or merely advisable for the proper implementation, execution and settlement of this resolution and of the Plan.

Nine. - Authorization to the Board of Directors, with express power of substitution, for the derivative acquisition of treasury shares, directly or through Group companies.

Authorise the acquisition of shares of Línea Directa Aseguradora, S.A., Compañía de Seguros y Reaseguros by the Company and its subsidiaries, pursuant to the provisions of the Capital Companies Act, in compliance with the requirements established by the legislation in force at any given time and under the following terms and conditions:

a) The acquisitions may be carried out directly by the Company or indirectly through its subsidiaries and must be formalised by means of purchase and sale, exchange or any other legal transaction valid under law.
b) The aggregate nominal value of the shares to be acquired, together, where applicable, with those already held directly or indirectly, shall not exceed the maximum percentage permitted by law at any given time.
c) The acquisition price per share shall be no less than the nominal value and no more than the stock market price on the acquisition date increased by 10%.
d) This authorisation is granted for a period of five years from the date of this General Shareholders' Meeting.

For the purposes of the provision set out in the final paragraph of Article 146.1(a) of the Capital Companies Act, it is authorised that the shares acquired by the Company or its subsidiaries pursuant to this authorisation may be used, in whole or in part, for delivery to the employees or directors of the Company or its subsidiaries, either directly or as a result of the exercise of option rights held by them.

Authorise the Board of Directors, with express powers of substitution and on the broadest terms, to exercise the authorisation granted under this resolution and to implement the other provisions contained herein

Tenth. - Authorisation to the Board of Directors, with powers of substitution, for a maximum period of five years, to increase the share capital in accordance with Article 297.1(b) of the Capital Companies Act, up to one half of the share capital as at the date of the authorisation.

To authorise the Board of Directors, as broadly as may be required by law, so that, pursuant to Article 297.1(b) of the Capital Companies Act, it may increase the share capital on one or more occasions and at any time within the period of five years from the date of this General Shareholders' Meeting, up to a maximum nominal amount of 21.768.336,80 euros, equivalent to one half of the Company's share capital as at the date of approval of this resolution.

Any share capital increases implemented under this authorisation shall be carried out by the issue and placing in circulation of new shares—with or without share premium—paid for by cash contributions. In connection with each increase, it shall be for the Board of Directors to decide whether the new shares to be issued are ordinary, preferred, redeemable, non-voting or of any other type permitted by law. Likewise, the Board of Directors may determine, in all matters not provided for herein, the terms and conditions of the share capital increases and the characteristics of the shares, as well as freely offer the new shares that are not subscribed within the period(s) for exercising pre-emptive subscription rights. The Board of Directors may also provide that, in the event of an incomplete subscription, the capital shall be increased only by the amount of the subscriptions actually made and may amend the articles of the Company's Bylaws relating to the share capital and the number of shares. The shares issued pursuant to this authorisation may be used to meet the conversion of convertible securities issued or to be issued by the Company or by companies within its group.

Where applicable, the Company shall apply for admission to trading, on official or unofficial secondary markets, whether organised or not, in Spain or abroad, of the shares issued pursuant to this delegation, and the Board of Directors is authorised to carry out the steps and actions necessary for admission to listing before the competent bodies of the various Spanish or foreign securities markets.

The Board of Directors is expressly authorised, in turn, to further delegate, pursuant to Article 249 bis of the Capital Companies Act, the delegated powers referred to in this resolution.

Eleventh. - Authorisation to the Board of Directors, with powers of substitution, for a maximum period of five years, to issue securities convertible into new shares of the Company, as well as warrants (options to subscribe for new shares of the Company). Establishment of the criteria for determining the bases and terms of conversion and granting the Board of Directors the power to increase the share capital by the amount necessary.

To authorise the Board of Directors, under the general regime governing the issuance of debentures and in accordance with Articles 297 and 511 of the Capital Companies Act and Article 319 of the Commercial Registry Regulations, to issue securities under the following terms and conditions:

1. Securities covered by the issuance. -The securities to which this authorisation refers are debentures, bonds, preferred shares and any other similar securities convertible into new shares of the Company, as well as warrants (options to subscribe for new shares of the Company).

2. Term of the delegation. - The issuance of the securities covered by this authorisation may be carried out on one or more occasions within a maximum period of five (5) years from the date of this General Shareholders' Meeting.

3. Maximum amount of the authorisation. -The maximum aggregate nominal amount of the issue(s) of securities resolved under this authorisation shall be EUR 1000 million or its equivalent in any other currency. For the purposes of calculating the above limit, in the case of warrants, the sum of the premiums and exercise prices of the warrants of the issues resolved under this authorisation shall be taken into account.

4. Scope of the authorisation.- This authorisation extends, as broadly as may be required by law, to the determination of the various aspects and terms and conditions of each issue, including, by way of example and without limitation: its amount, always within the above aggregate quantitative limit; the place of issue—Spain or abroad—and the currency and, where foreign, its euro equivalent; the specific instrument to be issued, whether bonds or debentures, including

subordinated instruments, warrants (which may in turn be settled by physical delivery of the shares or, where applicable, by cash settlement of differences), or any other form permitted by law; the issue date(s); the number of securities and their nominal value, which in the case of convertible bonds or debentures shall not be lower than the nominal value of the shares; in the case of warrants and similar instruments, the issue price and/or premium, the exercise price—which may be fixed or variable—and the applicable procedure, term and other conditions; the interest rate, fixed or floating; the coupon payment dates and procedures; whether the instrument issued is perpetual or redeemable and, in the latter case, the redemption term and maturity date(s); the guarantees, the redemption type, premiums and lots; the form of representation, by certificates or book-entry; the inclusion of anti-dilution provisions; the placement and subscription regime; admission to listing; the ranking of the securities and any subordination provisions; the governing law of the issue; and, in general, any other term of the issue, as well as, where applicable, the appointment of the bondholders' representative (comisario) and approval of the fundamental rules governing the legal relationship between the Company and the syndicate of holders of the securities issued, if the constitution of such syndicate is required or is decided.

5. Bases and terms of conversion. - In the event of issuing convertible securities (including debentures or bonds), and for the purposes of determining the bases and terms of conversion, it is agreed to establish the following criteria:

   a) The securities issued pursuant to this resolution shall be convertible into newly issued shares of the Company pursuant to a fixed or variable conversion ratio, determined or determinable. The Board of Directors is authorised to determine whether they are mandatorily or voluntarily convertible and, if voluntarily convertible, whether conversion is at the option of the holder and/or of the Company, with the frequency and within the term established in the issue resolution, which may not exceed thirty (30) years from the issue date.
   b) For conversion purposes, the securities shall be valued at their nominal amount, and the shares at the fixed conversion price established in the Board of Directors' resolution implementing this authorisation, or at the variable conversion price to be determined on the date(s) indicated in the relevant Board of Directors' resolution, based on the Company's share trading price on the stock exchange on the date(s) or during the reference period(s) specified in that same resolution.
   c) If a fixed conversion ratio is established, the fixed conversion price may not be lower than the arithmetic mean of the closing prices of the Company's shares on the Spanish Continuous Market over a period to be determined by the Board of Directors of no more than three months and no less than five calendar days prior to the date on which the Board of Directors resolves to issue the securities or the date on which the subscribers pay for the securities, with a premium or, where applicable, a discount to such per-share price; however, if a discount to the per-share price is set, it may not exceed 25% of the value of the shares taken as reference in accordance with the foregoing.

d) If a variable conversion ratio is established, the share price for conversion purposes shall be the arithmetic mean of the closing prices of the Company's shares on the Spanish Continuous Market over a period to be determined by the Board of Directors of no more than three months and no less than five calendar days prior to the conversion date, with a premium or, where applicable, a discount to such per-share price. The premium or discount may differ for each conversion date of each issue (or, where applicable, each tranche of an issue); however, if a discount to the per-share price is set, it may not exceed 25% of the value of the shares taken as reference in accordance with the foregoing.

e) In no event may the value of the share for the purposes of the conversion ratio of the securities into shares be lower than its nominal value. Likewise, pursuant to Article 415 of the Capital Companies Act, debentures may not be converted into shares when the nominal value of the former is lower than that of the latter.

6. Bases and terms for the exercise of warrants and other similar securities.- In the case of issues of warrants, to which the provisions of the Capital Companies Act on convertible debentures shall apply by analogy, for the determination of the bases and terms of their exercise, the Board of Directors is authorised to determine, on the broadest terms, the criteria applicable to the exercise of the rights to subscribe for Company shares deriving from securities of this type issued under the authorisation granted hereby, applying to such issues the criteria established in section 5 above, with the necessary adaptations to make them compatible with the legal and financial regime applicable to this type of securities.

7. Other delegated powers.-This authorisation to the Board of Directors also includes, by way of example and without limitation, the delegation in its favour of the following powers:

a) The power to increase the share capital by the amount necessary to meet requests for conversion and/or exercise of share subscription rights. This power may only be exercised to the extent that the share capital increase resolved by the Board of Directors to implement the issue of the relevant convertible securities or warrants does not exceed the unused limit authorised at any given time by the General Shareholders' Meeting pursuant to Article 297.1(b) of the Capital Companies Act. This authorisation to increase share capital includes the power to issue and place in circulation, on one or more occasions, the shares representing such increase as may be necessary to effect the conversion and/or exercise of the share subscription rights, as well as to amend the articles of the Company's Bylaws relating to the amount of the share capital and the number of shares and, where applicable, to cancel the portion of such share capital increase that is not required for the conversion and/or exercise of share subscription rights.

b) The power to develop and specify the bases and terms of conversion and/or exercise of the share subscription rights deriving from the securities to be issued, taking into account the criteria set out in sections 5 and 6 above.

c) The delegation to the Board of Directors includes the broadest powers that may be required by law for the interpretation, implementation, execution and development of the resolutions for the issue of convertible securities or warrants, on one or more occasions, and the related share capital increase, granting it powers to remedy and supplement them to the extent necessary, as well as to comply with any legally required formalities to bring them to completion. Accordingly, it may remedy omissions or defects in such resolutions identified by any authorities, officials or bodies, whether Spanish or foreign, and it is also empowered to adopt any resolutions and execute any public or private documents it deems necessary or advisable to adapt the aforementioned resolutions for the issue of convertible securities or warrants and the related share capital increase to the oral or written registration qualifications (calificación) of the Commercial Registry or, in general, of any other competent Spanish or foreign authorities, officials or institutions.

8. Admission to trading.- Where applicable, the Company shall apply for admission to trading, on official or unofficial secondary markets, whether organised or not, in Spain or abroad, of the convertible securities or warrants issued by the Company pursuant to this delegation, and the Board of Directors is authorised, as broadly as may be required by law, to carry out the steps and actions necessary for admission to listing before the competent bodies of the various Spanish or foreign securities markets.

9. Guarantee of issues of convertible and/or exchangeable securities or warrants by subsidiaries.- The Board of Directors is also authorised to guarantee, on behalf of the Company, within the limits indicated above, new issues of convertible securities or warrants carried out by subsidiaries during the term of this resolution.

10. Power of substitution.- The Board of Directors is expressly authorised, in turn, to further delegate, pursuant to Article 249 bis of the Capital Companies Act, the powers referred to in this resolution.

Twelfth - Delegation of powers to interpret, complement, correct, execute and formalise the resolutions adopted by the General Shareholders' Meeting.

Notwithstanding the powers delegated in the foregoing resolutions, to empower the Board of Directors, with the express power to sub-delegate, the Chairman of the Board of Directors, the Chief Executive Officer, and the Secretary of the Board of Directors, to the fullest extent required by law, so that any of them may implement the foregoing resolutions, for which purpose they may: (i) establish, interpret, clarify, complete, develop, modify, correct errors or omissions and adapt the resolutions set out above subject to the verbal or written approval of the Mercantile Registry and any competent authority, official or entity; (ii) prepare and publish the legally required announcements; (iii) implement the above resolutions and issue any public and/or private document deemed necessary or advisable for their implementation; (iv) file any documentation with the Mercantile Registry or other competent registers; and (v) carry out any such acts as may be necessary or advisable for their satisfactory implementation and, in particular, for their registration with the Mercantile Registry or any other competent register.

Advisory point:

Thirteenth - Advisory vote on the 2025 Report on the Remuneration of the members of the Board of Directors.

To approve, in an advisory capacity, the annual remuneration report for the 2025 financial year, approved by the board of directors, the full text of which has been made available to the shareholders, together with the rest of the documentation of the General Meeting, from the date of its notice.

.

.